Article

FDA Approves Pralsetinib for RET-Mutant Medullary Thyroid Cancer

Author(s):

Pralsetinib (Gavreto) approved for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer.

The FDA has approved pralsetinib (Gavreto) for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy or RET fusion-positive thyroid cancer who require systemic therapy and who are refractory to radioactive iodine.1

The regulatory decision was based on data from the multicenter, open label, multicohort phase 1/2 ARROW trial (NCT03037385), where the safety and efficacy of pralsetinib was evaluated in patients with RET fusion—positive non–small cell lung cancer (NSCLC), RET-mutated MTC, RET fusion–positive thyroid cancer, and other RET-altered solid tumors.

Investigators prospectively identified these alterations in local laboratories through the use of next-generation sequencing, fluorescence in situ hybridization, or other tests. The main efficacy outcome measures evaluated in the trial consisted of overall response rate (ORR) and duration of response (DOR) per a blinded independent review committee via RECIST v1.1 criteria. Results showed that among 55 patients with advanced or metastatic RET-mutant MTC who had received prior cabozantinib (Cabometyx) or vandetanib, pralsetinib elicited an ORR of 60% (95% CI, 46%-73%). Additionally, 79% percent of responders experienced responses that persisted for 6 months or longer.

Click to continue reading on OncLive.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Monoclonal antibodies are used to treat lung cancer. They are created in a lab and designed to target specific proteins on cancer cells, stopping them from growing and dividing.
Gene therapy in lung cancer (LC) - isometric view 3d illustration
© 2025 MJH Life Sciences

All rights reserved.